0000000000188104

AUTHOR

Marta Cabibbo

showing 3 related works from this author

Inhalable Formulation Based on Lipid–Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast

2022

Here, novel lipid-polymer hybrid nanoparticles (LPHNPs), targeted to lung macrophages, were realized as potential carriers for Roflumilast administration in the management of chronic obstructive pulmonary disease (COPD). To achieve this, Roflumilast-loaded fluorescent polymeric nanoparticles, based on a polyaspartamide-polycaprolactone graft copolymer, and lipid vesicles, made from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-distearoyl-sn-glycero-phosphoethanolamine-N-(polyethylene glycol)-mannose, were properly combined using a two-step method, successfully obtaining Roflumilast-loaded hybrid fluorescent nanoparticles (Man-LPHFNPs@Roflumilast). These exhibit colloidal size and a ne…

CyclopropanesPolymers and PlasticsPolymersMacrophagesPhosphatidylethanolaminesAminopyridinesBioengineeringPolyethylene GlycolsBiomaterialsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBenzamidesMaterials ChemistryHumansNanoparticlesParticle SizeMannoseBiomacromolecules
researchProduct

Inhalable polymeric microparticles as pharmaceutical porous powder for drug administration

2022

In this work, the production of inhalable polymeric microparticles with modulable porosity is described. The starting polymeric material was the PHEA-g-RhB-g-PLA graft copolymer, which was suitably processed by spray drying (SD). Thanks to the addition of AB (weight percentage equal to 10 and 20 % with respect to the polymer) in the liquid feed, three biocompatible matrices were obtained with an increasing porosity in terms of pore volume (from 0.015 to 0.024 cc/g) and pore average diameter (from 1.942 to 3.060 nm), a decreasing tapped density values (from 0.75 to 0.50), and favorable aerosolization characteristics. These differences were high-lighted also by a significant increase in the r…

Porous microparticlesDrug CarriersPolymersSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAdministration InhalationPharmaceutical SciencePulmonary administrationRapamycinPowdersParticle SizePorosityαβ-Poly(N-2-hydroxyethyl)-Dl-ASPARTAMIDE (PHEA)
researchProduct

Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis

2021

Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques

DrugBiodistributionmedia_common.quotation_subjectPharmaceutical ScienceExcipientNanoparticlelcsh:RS1-44102 engineering and technologyPharmaceutical formulationArticlelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compoundPhosphatidylcholinemedicine030304 developmental biologymedia_commonKOdia-PC0303 health sciencesrapamycin (Rapa)technology industry and agriculture021001 nanoscience & nanotechnologyIn vitromacrophage targetingpolymeric nanoparticleschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPolycaprolactoneBiophysicsatherosclerosis0210 nano-technologymedicine.drugPharmaceutics
researchProduct